clioquinol has been researched along with Parkinson Disease in 7 studies
Clioquinol: A potentially neurotoxic 8-hydroxyquinoline derivative long used as a topical anti-infective, intestinal antiamebic, and vaginal trichomonacide. The oral preparation has been shown to cause subacute myelo-optic neuropathy and has been banned worldwide.
5-chloro-7-iodoquinolin-8-ol : A monohydroxyquinoline that is quinolin-8-ol in which the hydrogens at positions 5 and 7 are replaced by chlorine and iodine, respectively. It has antibacterial and atifungal properties, and is used in creams for the treatment of skin infections. It has also been investigated as a chelator of copper and zinc ions for the possible treatment of Alzheimer's disease.
Parkinson Disease: A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Clioquinol treatment significantly prevented dopaminergic neurodegeneration and reduced α-synuclein-associated pathology in LB-injected mice, while no differences were observed with Zn supplementation." | 1.72 | The Zinc Ionophore Clioquinol Reduces Parkinson's Disease Patient-Derived Brain Extracts-Induced Neurodegeneration. ( Bezard, E; Bohic, S; Dehay, B; Doudnikoff, E; Teil, M; Thiolat, ML, 2022) |
| "Clioquinol (CQ) has been shown to have therapeutic benefits in rodent models of neurodegenerative disorders." | 1.56 | Clioquinol improves motor and non-motor deficits in MPTP-induced monkey model of Parkinson's disease through AKT/mTOR pathway. ( Cheng, A; Huang, C; Liu, W; Luo, Q; Shi, L; Shi, R; Xia, Y; Zeng, W; Zhengli, C, 2020) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (42.86) | 29.6817 |
| 2010's | 1 (14.29) | 24.3611 |
| 2020's | 3 (42.86) | 2.80 |
| Authors | Studies |
|---|---|
| Teil, M | 1 |
| Doudnikoff, E | 1 |
| Thiolat, ML | 1 |
| Bohic, S | 1 |
| Bezard, E | 1 |
| Dehay, B | 1 |
| Shi, L | 1 |
| Huang, C | 1 |
| Luo, Q | 1 |
| Xia, Y | 1 |
| Liu, W | 1 |
| Zeng, W | 1 |
| Cheng, A | 1 |
| Shi, R | 1 |
| Zhengli, C | 1 |
| Pretsch, D | 1 |
| Rollinger, JM | 1 |
| Schmid, A | 1 |
| Genov, M | 1 |
| Wöhrer, T | 1 |
| Krenn, L | 1 |
| Moloney, M | 1 |
| Kasture, A | 1 |
| Hummel, T | 1 |
| Pretsch, A | 1 |
| Sandor, C | 1 |
| Robertson, P | 1 |
| Lang, C | 1 |
| Heger, A | 1 |
| Booth, H | 1 |
| Vowles, J | 1 |
| Witty, L | 1 |
| Bowden, R | 1 |
| Hu, M | 1 |
| Cowley, SA | 1 |
| Wade-Martins, R | 1 |
| Webber, C | 1 |
| Kaur, D | 2 |
| Rajagopalan, S | 2 |
| Andersen, JK | 2 |
| Cole, GM | 1 |
| Yantiri, F | 1 |
| Kumar, J | 1 |
| Mo, JQ | 1 |
| Boonplueang, R | 1 |
| Viswanath, V | 1 |
| Jacobs, R | 1 |
| Yang, L | 1 |
| Beal, MF | 1 |
| DiMonte, D | 1 |
| Volitaskis, I | 1 |
| Ellerby, L | 1 |
| Cherny, RA | 1 |
| Bush, AI | 1 |
7 other studies available for clioquinol and Parkinson Disease
| Article | Year |
|---|---|
The Zinc Ionophore Clioquinol Reduces Parkinson's Disease Patient-Derived Brain Extracts-Induced Neurodegeneration.
Topics: alpha-Synuclein; Animals; Brain; Clioquinol; Dopamine; Dopaminergic Neurons; Humans; Ionophores; Mic | 2022 |
Clioquinol improves motor and non-motor deficits in MPTP-induced monkey model of Parkinson's disease through AKT/mTOR pathway.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Clioquinol; Disease Models, Animal; Haplorhin | 2020 |
Prolongation of metallothionein induction combats Aß and α-synuclein toxicity in aged transgenic Caenorhabditis elegans.
Topics: Aging; alpha-Synuclein; Alzheimer Disease; Amyloid beta-Peptides; Animals; Animals, Genetically Modi | 2020 |
Transcriptomic profiling of purified patient-derived dopamine neurons identifies convergent perturbations and therapeutics for Parkinson's disease.
Topics: Autopsy; Cells, Cultured; Clioquinol; Dopamine; Dopaminergic Neurons; Gene Expression Profiling; Gen | 2017 |
Chronic expression of H-ferritin in dopaminergic midbrain neurons results in an age-related expansion of the labile iron pool and subsequent neurodegeneration: implications for Parkinson's disease.
Topics: Aging; Animals; Apoferritins; Chelating Agents; Clioquinol; Dopamine; Gene Expression Regulation; Ir | 2009 |
Ironic fate: can a banned drug control metal heavies in neurodegenerative diseases?
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Alzheimer Disease; Animals; Clioquinol; Ferritins; Gen | 2003 |
Genetic or pharmacological iron chelation prevents MPTP-induced neurotoxicity in vivo: a novel therapy for Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Blotting, Wes | 2003 |